Sign in or create an account to add this stock to your watchlist.
About Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Debt
Debt-to-Equity Ratio0.22
Current Ratio7.20
Quick Ratio7.20
Price-To-Earnings
Trailing P/E Ratio-11.26
Forward P/E Ratio-10.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.11 million
Price / Sales147.78
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book9.34
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,143.99%
Return on Equity-77.27%
Return on Assets-54.40%
Miscellaneous
Employees80
Outstanding Shares52,860,000
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The biopharmaceutical company earned $1 million during the quarter, compared to analyst estimates of $1.82 million. Fate Therapeutics had a negative return on equity of 77.27% and a negative net margin of 1,143.99%. Fate Therapeutics's quarterly revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
8 analysts have issued 12-month price targets for Fate Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Fate Therapeutics' share price to reach $16.1667 in the next year. View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (5/15/2018)
- 2. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018)
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP) and Acorda Therapeutics (ACOR).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)
- Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)
- Dr. Chris M. Storgard, Chief Medical Officer (Age 52)
- Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)
- Dr. Stewart Abbot, Chief Devel. Officer (Age 51)
Has Fate Therapeutics been receiving favorable news coverage?
News articles about FATE stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fate Therapeutics earned a news sentiment score of 0.13 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (12.59%), Franklin Resources Inc. (11.06%), BlackRock Inc. (5.49%), Artal Group S.A. (1.61%), Victory Capital Management Inc. (1.09%) and Northern Trust Corp (0.94%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.
Which major investors are selling Fate Therapeutics stock?
FATE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Franklin Resources Inc., Neuberger Berman Group LLC and Hochman Cole Investment Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.
Which major investors are buying Fate Therapeutics stock?
FATE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Artal Group S.A., JPMorgan Chase & Co., Victory Capital Management Inc., Columbus Circle Investors, Northern Trust Corp and Nuveen Asset Management LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $11.49.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $595.72 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $16.1667, suggesting that the stock has a possible upside of 40.70%. The high price target for FATE is $20.00 and the low price target for FATE is $7.00. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 2.88 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $16.1667 | $16.1667 | $7.6667 | $7.20 |
| Price Target Upside: | 40.70% upside | 64.80% upside | 10.15% upside | 65.52% upside |
Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History
Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Fate Therapeutics (NASDAQ:FATE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.89%
Institutional Ownership Percentage: 74.39%
Fate Therapeutics (NASDAQ FATE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/16/2017 | Cindy Tahl | General Counsel | Sell | 8,091 | $3.85 | $31,150.35 | |  |
| 10/16/2017 | Daniel D Shoemaker | Insider | Sell | 13,225 | $3.87 | $51,180.75 | | |
| 11/23/2016 | Chris Storgard | Insider | Buy | 37,593 | $2.66 | $99,997.38 | 9,090 | |
| 11/23/2016 | William H Rastetter | Director | Buy | 375,939 | $2.66 | $999,997.74 | | |
| 6/12/2014 | Peter D Flynn | Insider | Sell | 6,488 | $7.00 | $45,416.00 | | |
| 6/10/2014 | Peter D Flynn | Insider | Sell | 3,305 | $7.00 | $23,135.00 | | |
| 5/1/2014 | Peter D Flynn | Insider | Sell | 9,793 | $7.07 | $69,236.51 | | |
| 4/4/2014 | Peter D Flynn | Insider | Sell | 5,889 | $8.00 | $47,112.00 | | |
| 4/2/2014 | Christian Weyer | Insider | Sell | 10,000 | $9.02 | $90,200.00 | | |
| 4/1/2014 | J Scott Wolchko | Insider | Sell | 20,000 | $9.64 | $192,800.00 | | |
| 3/31/2014 | Daniel D Shoemaker | CTO | Sell | 8,653 | $9.86 | $85,318.58 | | |
| 10/4/2013 | John Mendlein | Director | Buy | 16,667 | $6.00 | $100,002.00 | | |
| 10/4/2013 | Venture Fund Vi Lp Arch | Major Shareholder | Buy | 833,333 | $6.00 | $4,999,998.00 | | |
(Data available from 1/1/2013 forward)
Fate Therapeutics (NASDAQ FATE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Fate Therapeutics Inc (FATE) to Post -$0.26 EPS
www.americanbankingnews.com - May 26 at 1:24 AM |
 | Analysis: Positioning to Benefit within Beazer Homes, Tejon Ranch, Ladder Capital, Fate Therapeutics, Benefitfocus, and H&E Equipment Services — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - May 22 at 8:19 AM |
 | Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene ...
globenewswire.com - May 16 at 5:42 PM |
| Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
finance.yahoo.com - May 16 at 8:19 AM |
| Zacks Investment Research Lowers Fate Therapeutics (FATE) to Sell
www.americanbankingnews.com - May 15 at 10:58 PM |
| Analyzing Fate Therapeutics (FATE) and OXiGENE (MATN)
www.americanbankingnews.com - May 12 at 7:19 PM |
| Fate Therapeutics (FATE) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 11 at 2:50 PM |
 | Fate Therapeutics misses by $0.05, misses on revenue
seekingalpha.com - May 11 at 8:27 AM |
| Fate Therapeutics' (FATE) CEO Scott Wolchko on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 8:27 AM |
| Edited Transcript of FATE earnings conference call or presentation 10-May-18 9:00pm GMT
finance.yahoo.com - May 11 at 8:27 AM |
 | 5 Stocks Moving In Thursday's After-Hours Session
www.benzinga.com - May 10 at 5:57 PM |
| Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
finance.yahoo.com - May 10 at 5:57 PM |
| Fate Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:57 PM |
| $2.02 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - May 10 at 2:38 AM |
| Fate Therapeutics (FATE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 9 at 1:23 AM |
| Fate Therapeutics (FATE) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 11:57 PM |
| Zacks: Analysts Anticipate Fate Therapeutics (FATE) to Post -$0.22 EPS
www.americanbankingnews.com - May 8 at 7:16 PM |
| Fate Therapeutics (FATE) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 7 at 2:50 AM |
 | BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million
www.reuters.com - May 4 at 5:33 PM |
| Fate Therapeutics (FATE) Lifted to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 4 at 12:13 AM |
| Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:24 PM |
 | Adicet Bio appoints Elizabeth "EJ" Read, MD as Chief Technology Officer
www.prnewswire.com - May 2 at 5:36 PM |
| Fate Therapeutics (FATE) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - May 2 at 1:15 PM |
| Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 8:21 AM |
| -$0.22 EPS Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - April 21 at 3:22 PM |
| Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual ...
globenewswire.com - April 18 at 5:45 PM |
| Fate Therapeutics (FATE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 1:25 AM |
| Stock Traders Purchase Large Volume of Call Options on Fate Therapeutics (FATE)
www.americanbankingnews.com - April 13 at 6:56 AM |
| Fate Therapeutics Inc’s (NASDAQ:FATE) Shift From Loss To Profit
finance.yahoo.com - April 10 at 5:29 PM |
| $2.34 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - April 6 at 2:50 AM |
| Fate Therapeutics (FATE) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 4 at 3:14 PM |
| Fate Therapeutics (FATE) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM |
| Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018
finance.yahoo.com - April 3 at 8:24 AM |
| 3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey
seekingalpha.com - April 2 at 8:40 AM |
| Fate Therapeutics' (FATE) Buy Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - April 2 at 8:20 AM |
| Fate Therapeutics (FATE) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM |
| Fate Therapeutics (FATE) Raised to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:06 PM |
| Edited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMT
finance.yahoo.com - March 30 at 5:30 PM |
 | Fate Therapeutics (FATE) Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer
www.streetinsider.com - March 30 at 8:23 AM |
| Short Interest in Fate Therapeutics (FATE) Grows By 47.8%
www.americanbankingnews.com - March 30 at 3:38 AM |
| Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer ...
globenewswire.com - March 29 at 5:30 PM |
| Fate Therapeutics' (FATE) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 29 at 4:10 PM |
| Fate Therapeutics' FATE-NK100 shows encouraging action in early-stage ovarian cancer study; shares ahead 5% premarket
seekingalpha.com - March 29 at 9:16 AM |
| Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
finance.yahoo.com - March 29 at 8:28 AM |
| Fate Therapeutics (FATE) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 28 at 6:00 PM |
| Edited Transcript of FATE earnings conference call or presentation 5-Mar-18 10:00pm GMT
finance.yahoo.com - March 27 at 5:14 PM |
| Fate Therapeutics (FATE) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM |
| Fate Therapeutics (FATE) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - March 24 at 11:24 AM |
| Fate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune
www.streetinsider.com - March 21 at 5:38 PM |
| Fate Therapeutics (FATE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 20 at 11:56 AM |
Fate Therapeutics (NASDAQ:FATE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement
Fate Therapeutics (NASDAQ FATE) Stock Chart for Saturday, May, 26, 2018
Loading chart…
